Advertisement

Neuropharmacology of Passiflora Genus

  • Amritpal Singh Saroya
  • Jaswinder Singh
Chapter

Abstract

P. incarnata is addressed by several names like maypop, purple passionflower, true passionflower, wild apricot and wild passion vine and is a member of family Passifloraceae. P. incarnata is common to the southeast United States. The dried herb is used in medicine and collected after some of the berries have matured.

References

  1. Akhondzadeh S, Kashani L, Mobaseri M, Hosseini SH, Nikzad S, Khani M. Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. J Clin Pharm Ther. 2001a;26:369–73.CrossRefPubMedGoogle Scholar
  2. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001b;26:363–7.CrossRefPubMedGoogle Scholar
  3. Aoyagi N, Kimura R, Murata T. Studies on Passiflora incarnata dry extract. I. Isolation of maltol and pharmacological action of maltol and ethyl maltol. Chem Pharm Bull. 1974;22:1008–13.CrossRefPubMedGoogle Scholar
  4. Appel K, Rose T, Fiebich B, Kammler T, Hoffmann C, Weiss G. Modulation of the γ-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res. 2011;25:838–43.CrossRefPubMedGoogle Scholar
  5. Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU. Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. J Anesth. 2012;26:39–44.CrossRefPubMedGoogle Scholar
  6. Bennati E. Quantitative determination of harmane and harmine in extract of Passiflora incarnata [in Italian]. Boll Chim Farm. 1971;110:664–9.PubMedGoogle Scholar
  7. Brasseur T, Angenot L. The pharmacognosy of the passion flower [in French]. J Pharm Belg. 1984;39:15–22.PubMedGoogle Scholar
  8. Brown E, Hurd NS, McCall S, Ceremuga TE. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat. AANA J. 2007;75:333–7.Google Scholar
  9. Dantas L-P , Ribeiro Ade O, Almeida-Souza L-M de, Groppo F-C. Effects of Passiflora incarnata and midazolam for control of anxiety in patients undergoing dental extraction. Med Oral Patol Oral Cir Bucal 2017; 22:e95–e101.Google Scholar
  10. de Castro PC, Hoshino A, da Silva JC, Mendes FR. Possible anxiolytic effect of two extracts of Passiflora quadrangularis L. in experimental models. Phytother Res. 2007;21:481–4.CrossRefPubMedGoogle Scholar
  11. Dhawan K, Sharma A. Prevention of chronic alcohol and nicotine-induced azospermia, sterility and decreased libido, by a novel tri-substituted benzoflavone moiety from Passiflora incarnata Linneaus in healthy male rats. Life Sci. 2002;71:3059–69.CrossRefPubMedGoogle Scholar
  12. Dhawan K, Kumar R, Kumar S, Sharma A. Correct identification of Passiflora incarnata Linn., a promising herbal anxiolytic and sedative. J Med Food. 2001a;4:143–9.CrossRefGoogle Scholar
  13. Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. J Ethnopharmacol. 2001b;78:165–70.CrossRefPubMedGoogle Scholar
  14. Dhawan K, Kumar S, Sharma A. Anxiolytic activity of aerial and underground parts of Passiflora incarnata. Fitoterapia. 2001c;72:922–6.CrossRefPubMedGoogle Scholar
  15. Dhawan K, Kumar S, Sharma A. Reversal of morphine tolerance and dependence by Passiflora incarnata – a traditional medicine to combat morphine addiction. Pharm Biol. 2001d;40:576–80.CrossRefGoogle Scholar
  16. Dhawan K, Kumar S, Sharma A. Nicotine reversal effects of the benzoflavone moiety from Passiflora incarnata Linneaus in mice. Addict Biol. 2002a;7:435–41.CrossRefPubMedGoogle Scholar
  17. Dhawan K, Kumar S, Sharma A. Suppression of alcohol-cessation-oriented hyper-anxiety by the benzoflavone moiety of Passiflora incarnata Linneaus in mice. J Ethnopharmacol. 2002b;81:239–44.CrossRefPubMedGoogle Scholar
  18. Dhawan K, Dhawan S, Chhabra S. Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic. J Pharm Pharm Sci. 2003;6:215–22.PubMedGoogle Scholar
  19. Dhawan K, Dhawan S, Sharma A. Passiflora: a review update. J Ethnopharmacol. 2004;94:1–23.CrossRefPubMedGoogle Scholar
  20. Elsas SM, Rossi DJ, Raber J, White G, Seeley CA, Gregory WL, Mohr C, Pfankuch T, Soumyanath A. Passiflora incarnata L. (Passionflower) extracts elicit GABA currents in hippocampal neurons in vitro, and show anxiogenic and anticonvulsant effects in vivo, varying with extraction method. Phytomedicine. 2010;17:940–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Fellows EJ, Smith CS. The chemistry of Passiflora incarnata. J Pharm Sci. 1938;7:565–73.Google Scholar
  22. Gavaseli NM. Studies on the flavonoids of Passíflora incarnata. SoobSc. Akad. Nauk. gruz. SSR 1970;60:353–6.Google Scholar
  23. Grundmann O, Wang MGGP, Butterweck V. Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system. Planta Med. 2008;74:1769–73.CrossRefPubMedGoogle Scholar
  24. Hans W, Penma KG, Pearson T, Lehmann RP. Pharmacognosy and phenotypes of passionflower (Passiflora incarnata L.). Biol Pharm Bull. 2010;33:1015–8.CrossRefGoogle Scholar
  25. Jun D, YuJuan Z, Meng BM, Li HW, Li L. Anxiolytic and sedative activities of Passiflora edulis f. flavicarpa. J Ethnopharmacol. 2010;128:148–53.CrossRefGoogle Scholar
  26. Krenn L. Passion flower (Passiflora incarnata L.)-a reliable herbal sedative. Wien Med Wochenschr. 2002;152:404–6.CrossRefPubMedGoogle Scholar
  27. Li QM, van den Heuvel H, Delorenzo O, et al. Mass spectral characterization of C-glycosidic flavonoids isolated from a medicinal plant (Passiflora incarnata ). J Chromatogr. 1991;562:435–46.CrossRefPubMedGoogle Scholar
  28. Menghini A, Mancini LA. TLC determination of flavonoid accumulation in clonal populations of Passiflora incarnata L. Pharmacol Res Commun. 1988;20:113–6.CrossRefPubMedGoogle Scholar
  29. Miroddi M, Calapai G, Navarra M, Minciullo PL, Gangemi S. Passiflora incarnata L.: Ethnopharmacology, clinical application, safety and evaluation of clinical trials. J Ethnopharmacol. 2013;150:791–804.CrossRefPubMedGoogle Scholar
  30. Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg. 2008;106:1728–32.CrossRefPubMedGoogle Scholar
  31. Nassiri-Asl M, Shariati-Rad S, Zamansoltani F. Anticonvulsant effects of aerial parts of Passiflora incarnata extract in mice: involvement of benzodiazepine and opioid receptors. BMC Complement Altern Med. 2007;7:26.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Nassiri-Asl M, Zamansoltani F, Shariati-Rad S. Possible role of GABAA-benzodiazepine receptor in anticonvulsant effects of Pasipay in rats. Zhong Xi Yi Jie He Xue Bao. 2008;6:1170–3.CrossRefPubMedGoogle Scholar
  33. Neu R. Composition of Passiflora incarnata. III. The alkaloid of Passiflora, 3-methyl-4-carbolin (2′-methyl-(pyridino-3′, 4′ : 2,3-indole)). Arzneimittelforschung. 1956;6:94–8.PubMedGoogle Scholar
  34. Patel SS, Mohamed Saleem TS, Ravi V, Shrestha B, Verma NK, Gauthaman G. Passiflora incarnata Linn.: a phytopharmacological review. Int J Green Pharm. 2009;3:277–80.CrossRefGoogle Scholar
  35. Pereira CAM, Vilegas JHY. Chemical and pharmacological constituents of Passiflora alata Dryander, Passiflora edulis Sims and Passiflora incarnata L. Revista Brasileira de Plantas Medicinais. 2000;31–12.Google Scholar
  36. Petry RD, Reginatto F, de-Paris F, Gosmann G, Salgueiro JB, Quevedo J, Kapczinski F, Ortega GG, Schenkel EP. Comparative pharmacological study of hydroethanol extracts of Passiflora alata and Passiflora edulis leaves. Phytother Res. 2001;15:162–4.CrossRefPubMedGoogle Scholar
  37. Reginatto FH, Gosmann G, Schripsema J, Schenkel EP. Assay of quadranguloside, the major saponin of leaves of Passiflora alata, by HPLC-UV. Phytochem Anal. 2004;15:195–7.CrossRefPubMedGoogle Scholar
  38. Rehwald A, Meier B, Sticher O. Qualitative and quantitative reversed-phase high-performance liquid chromatography of flavonoids in Passiflora incarnata L. Pharm Acta Helv. 1994;69:153–8.CrossRefGoogle Scholar
  39. Santos KC, Santos CA, de Oliveira RM. Passiflora actinia Hooker extracts and fractions induce catalepsy in mice. J Ethnopharmacol. 2005;100:306–9.CrossRefPubMedGoogle Scholar
  40. Schmidt P, Ortega GG. Passion flowers: assay of the total flavonoid contents in passiflorae herba. Dtsch Apotheker-Zeitung. 1993;133:17–20. 23-26Google Scholar
  41. Sena LM, Zucolotto SM, Reginatto FH, Schenkel EP, De Lima TC. Neuropharmacological activity of the pericarp of Passiflora edulis flavicarpa degener: putative involvement of C-glycosylflavonoids. Exp Biol Med. 2009;234:967–75.CrossRefGoogle Scholar
  42. Singh B, Singh D, Goel RK. Dual protective effect of Passiflora incarnata in epilepsy and associated post-ictal depression. J Ethnopharmacol. 2012;139:273–9.CrossRefPubMedGoogle Scholar
  43. Wolfman C, Viola H, Paladini A, Dajas F, Medina JH. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol Biochem Behav. 1994;47:1–4.CrossRefPubMedGoogle Scholar
  44. Zhang J, Koike R, Yamamoto A, Akihisa T. Glycosidic inhibitors of Melanogenesis from leaves of Passiflora edulis. Chem Biodivers. 2013;10:1851–65.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Amritpal Singh Saroya
    • 1
  • Jaswinder Singh
    • 2
  1. 1.Herbal ConsultantMohaliIndia
  2. 2.Department of PharmacologySri Guru Ram Das Institute of Medical ScienceAmritsarIndia

Personalised recommendations